ERBB2 and breast cancer: Further, one might hypothesize that the low incidence of CDK12 amplification in the whole FMI database most likely represents the fact that ERBB2‐amplified breast cancer especially lobular types might not have been submitted to FMI testing as such cases undergo primarily HER2‐directed therapy regimens.